ProLung’s research team is continually expanding clinical evidence for the ProLung Test, bioconductance, and non-invasive lung cancer risk stratification through ongoing clinical studies and trials.
The FML-204 study was a prospective study of 41 patients to evaluate the safety and efficacy of non-invasive, non-radiating bioconductance measurements in distinguishing between malignant and benign lung lesions. No adverse events reported.
Transcutaneous Computed Bioconductance Measurement in Lung Cancer
Rex C. Yung, MD; Ming Ying Zeng, MD; Gregory J. Stoddard, MS; Michael Garff, BS; and Karleen Callahan, PhD.
J Thorac Oncol. Vol. 7, No. 4, April 2012
This study is intended to evaluate the safety and efficacy of the ProLung Test for risk stratification of patients with pulmonary lesions identified by CT that are suspicious for lung cancer. PL-208 is being conducted at the following research sites:
Huntsman Cancer Institute
Henry Ford Hospital
University of California Los Angeles
Loyola University Health System
Greater Baltimore Medical Center
University of Minnesota Masonic Cancer Center
Medical University of South Carolina
Stanford Health Care
MD Anderson Cancer Center
Intermountain Health Care
University of California San Diego
Wake Forest Baptist Health
Beth Israel Deaconess Boston
The PL-209 repeatability study objectives include quantifying the effects of sex, body mass index (BMI), day-to-day subject variability of a single device when volume – average thoracic bioconductance was measured with the ProLung Test. The study enrolled sixty subjects.
If you have been diagnosed with an indeterminate pulmonary nodule, you may be eligible to participate in a ProLung clinical trial.
Email us at ItsAboutTime@prolunginc.com and we will connect you to the nearest testing location.